Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial.

The article discusses the ARISE-HF trial, which aimed to evaluate the safety and efficacy of a novel aldose reductase inhibitor (AT-001) in patients with diabetic cardiomyopathy (DbCM) and stage B heart failure (HF). DbCM is a complication of type 2 diabetes mellitus (T2DM) that can lead to structural and functional abnormalities in the heart. The study found that AT-001 did not significantly improve exercise capacity compared to placebo, but there was a potential benefit in patients not receiving other cardioprotective drugs. However, further research is needed to confirm these findings and determine the clinical role of AT-001 in combination with other therapies. [Extracted from the article]